‼️ Wild that this isn’t already standard. If DNA synthesis can be ordered by mail, screening and recordkeeping should be mandatory. #AI is accelerating biosecurity risks — oversight needs to keep pace.

@StephenVLiu - the actual pCR rate is 34% based on the report. They left out 11 patients from the denominator. It is misleading…

Very excited about this upcoming trial using a validated clinicogenomic brain met prediction #AI model--intensified MRI surveillance is a simple, low-risk, and impactful intervention. So excited to be seeing interventional clinical trial designs like this. Would love to make something like this happen in lung! @pike_lab #ASCO2026 #lcsm

You don’t have to be a GI oncologist to appreciate this moment. #ASCO2026

The five newest attendings in the @MassGenBrigham thoracic oncology group! 💅🏻💪 #ASCO2026 @MGHThoracicOnc

‼️ Big news in the early detection world: Galleri (a methylation-based multi-cancer detection test) failed to meet its primary endpoint of reduction of stage III/IV cancer diagnosis in a large prospective randomized trial with the NHS. #ASCO2026 - PPV ~50%, and among the false positives, about half (n=404) underwent invasive procedures as part of their workup. 😬 - ~2/3 of people diagnosed with cancer had a negative Galleri test (false negative) - Some early signals of greater benefit in certain cancers but overall not powered for that. - Galleri arm detected more cancers, but the clinical benefit of this is not yet clear. - Important to remember that surrogate endpoints (stage III/IV diagnoses and stage IV diagnoses) do not correlate well with survival in all cancer types. ⭐️ My take: I think this type of cancer detection assay will have clinical value in some context(s), but we still have a ways to go before we know how to use it. Use in higher risk patients? Limit assay to detect only certain cancers? Lots of work to be done. 💪

FLAME study shows benefit of osi/chemo compared to osi alone in pts with EGFRm NSCLC who are ctDNA after 3 wks on osi. #ASCO2026 #lcsm Would love to see a study comparing osi/chemo to osi alone in pts who are ctDNA negative. Who can we safely spare the toxicity of chemo?

Groundbreaking talk by @JessicaJLinMD re: novel ALKi neladalkib. #ASCO2026 #lcsm - Lorlatinib-pretreated: ORR 26%, IC-ORR 21%, med DoR 17.6m (decent given lorlatinib’s potent ALK inhibition) - Initial TKI-naive results (n=44): ORR 86%, IC-ORR 78% - AE more mild than lorlatinib

This is key.

Wow—CROWN is the gift that keeps on giving. #ASCO2026 #lcsm - Median PFS STILL not reached after 7y! - Unprecedented CNS control - Resistance mechanisms primarily not on-target, speaking to the potency of ALK inhibition. - Disease control still very good even with dose reduction

Really impactful talk by Alex Potter (@alexandra_p_24) on long-term (5 years) quality of life after #LungCancer surgery. Data from the Boston Lung Cancer Study show survivors have high quality of life, comparable to the U.S. general population. Early detection matters—it can help lead to good long-term outcomes for patients!! #AATS2026

Such a privilege to be on the @UpstageLungCanc podcast discussing familial lung cancer risk and the future of #lungcancerscreening with @LeciaSequist and Hildy Grossman. #lcsm #AI @MassGeneralNews @MGHThoracicOnc

maybe this is not yet clear, so let me state it plainly: as of right now Anthropic, and really a small number of individuals at Anthropic, has the capacity to directly attack and cause major damage to the United States Government, China, and generally global superpowers. government agencies like the NSA do not have internal models or defense capabilities that outclass frontier models. if they chose to do so, they could likely exfiltrate top secret information from government systems, gain control over critical infrastructure including military infrastructure, sabotage or modify communications between members of government at the highest level, and potentially carry on activities for some time without detection. the thing about having access to a huge number of zerodays your adversaries don't know about is it gives you a massive asymmetric advantage. they did not exploit this to gain power or destabilize the world order. they publicly released the information that they had these capabilities and worked to mitigate these flaws. you should be grateful american frontier labs have proven themselves remarkably trustworthy and concerned with the public good. but it's critical you understand we are in a new regime. private entities now have power that directly rivals and impacts the government's monopoly on influence and violence. and anthropic is certainly not the only one, there's little chance OpenAI's internal models are far behind. this trend will accelerate on virtually every dimension, not slow down. my prediction for how it plays out is the relatively imminent seizure and nationalization of labs by the US government, sometime over the next two years. it's very tough for me to see how they accept the existence of this kind of threat. but this adds a whole new class of governance issues, as then we've handed these extremely wide-reaching capabilities from private entities to public ones.

Absolutely inspirational Patterson plenary lecture on #lungcancerscreening at AATS #ITSOS2025 by @DouglasEWood1!! Dr. Wood has been a relentless advocate and was instrumental in getting #lungcancerscreening covered by health insurance in the US. He also emphasized the need to simplify lung cancer screening guidelines: get rid of 15 years since quit, and use smoking duration instead of pack years to guide eligibility criteria (go w/ #Pottercriteria)

So impressed with @MaryPasquinelli’s work where she demonstrated that Sybil, an AI algorithm, can accurately predict 6-year #lungcancer risk from one baseline CT scan, in diverse cohorts, with minimal bias!! #WCLC25

One of the biggest influences on my career is Dr. Ross Camidge - a mentor and friend, an intellectual giant in the field of lung cancer who was diagnosed with this unforgiving disease himself. We are all at risk - and must all work to move the field. news.cuanschutz.edu/cancer-c…